|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
Q1 FY2022
As of Jun 30, 2021
|
Q4 FY2021
As of Mar 31, 2021
|
Q3 FY2021
As of Dec 31, 2020
|
Q2 FY2021
As of Sep 30, 2020
|
Q1 FY2021
As of Jun 30, 2020
|
Q4 FY2020
As of Mar 31, 2020
|
Q3 FY2020
As of Dec 31, 2019
|
Q2 FY2020
As of Sep 30, 2019
|
Q1 FY2020
As of Jun 30, 2019
|
Q4 FY2019
As of Mar 31, 2019
|
Q3 FY2019
As of Dec 31, 2018
|
Q2 FY2019
As of Sep 30, 2018
|
Q1 FY2019
As of Jun 30, 2018
|
Q4 FY2018
As of Mar 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Milestone receivable from Pfizer | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Income tax receivable | ||||||||||||||||||||
| Amount due from related party | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Marketable securities, non-current | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and shareholders’ deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Interest payable | ||||||||||||||||||||
| Interest payable (related party) | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Share-based compensation liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| License and milestone revenue | ||||||||||||||||||||
| Total deferred revenue | ||||||||||||||||||||
| Amounts due to Pfizer | ||||||||||||||||||||
| Cost share advance from Pfizer | ||||||||||||||||||||
| Operating lease liability | ||||||||||||||||||||
| Current maturities of long-term debt | ||||||||||||||||||||
| Amounts due to related parties | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred interest payable | ||||||||||||||||||||
| Deferred revenue, non-current | ||||||||||||||||||||
| Cost share advance from Pfizer, non-current | ||||||||||||||||||||
| Long-term operating lease liability | ||||||||||||||||||||
| Long-term debt, less current maturities | ||||||||||||||||||||
| Long-term debt, less current maturities (related party) | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ deficit: | ||||||||||||||||||||
| Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 97,028,258 and 94,858,446 issued and outstanding at December 31, 2022 and March 31, 2022, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total shareholders’ deficit | ||||||||||||||||||||
| Total liabilities and shareholders’ deficit | ||||||||||||||||||||
Loading...
